**Name of Journal: *World Journal of Gastrointestinal Oncology***

**Manuscript NO: 48207**

**Manuscript Type: ORIGINAL ARTICLE**

***Retrospective Study***

**multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers**

Mizrahi JD *et al*. Role of FOLFIRI in advanced biliary cancer

**Jonathan D Mizrahi, Valerie Gunchick, Kabir Mody, Lianchun Xiao, Phanikeerthi Surapaneni, Rachna T Shroff, Vaibhav Sahai**

**Jonathan D Mizrahi, Lianchun Xiao,** Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77005, United States

**Valerie Gunchick, Vaibhav Sahai,** Internal Medicine, University of Michigan, Ann Arbor, MI 48109, United States

**Kabir Mody, Phanikeerthi Surapaneni,** Division of Medical Oncology, Mayo Clinic Cancer Center, Jacksonville, FL 32224, United States

**Rachna T Shroff,** University of Arizona Cancer Center, University of Arizona, tucson, AZ 85724, United States

**ORCID number:** Jonathan D Mizrahi (0000-0002-3710-9742); Valerie Gunchick (0000-0002-9392-0644); Kabir Mody (0000-0003-3254-2990); Lianchun Xiao (0000-0003-0972-2766); Phanikeerthi Surapaneni (0000-0003-2712-7709); Rachna T Shroff (0000-0003-0066-2672); Vaibhav Sahai (0000-0003-1892-1548).

**Author contributions:** Sahai V, Shroff RT and Mody K designed the research study; Mizrahi JD, Gunchick V, Mody K, Surapaneni KP, Shroff RT and Sahai V collected the data; Xiao L, Mizrahi JD, Gunchick V and Sahai V analyzed and interpreted the data; Mizrahi JD, Gunchick V and Sahai V wrote the manuscript; All authors have read and approve the final manuscript.

**Institutional review board statement:** The study was reviewed and approved by the individual Institutional Review Boards at MD Anderson Cancer Center, University of Michigan and Mayo Clinic.

**Informed consent statement:** Informed consent was waived as patient data were collected and de-identified for analysis.

**Conflict-of-interest statement:** The authors report no conflicts of interest relevant to this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Corresponding author: Jonathan D Mizrahi, MD,** **Academic Fellow,** Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd Unit 463, Houston, TX 77030, United States. jdmizrahi@mdanderson.org

**Received:** May 8, 2019

**Peer-review started:** May 10, 2019

**First decision:** July 31, 2019

**Revised:** August 9, 2019

**Accepted:** September 12, 2019

**Article in press:** September 12, 2019

**Published online:** January 15, 2020

**Abstract**

***BACKGROUND***

Gemcitabine plus platinum is the standard of care first-line treatment for advanced biliary tract cancers (BTC). There is no established second-line therapy, and retrospective reviews report median progression-free survival (PFS) less than 3 mo on second-line therapy. Five-Fluorouracil plus irinotecan (FOLFIRI) is a commonly used regimen in patients with BTC who have progressed on gemcitabine plus platinum, though there is a paucity of data regarding its efficacy in this population.

***AIM***

To assess the efficacy of FOLFIRI in patients with biliary tract cancers.

***METHODS***

We retrospectively identified patients with advanced BTC who were treated with FOLFIRI at MD Anderson, University of Michigan and Mayo Clinic in Jacksonville. Data were collected on patient demographics, BTC subtype, response per RECIST v1.1, progression and survival.

***RESULTS***

Ninety-eight patients were included of which 74 (75%) had metastatic and 24 (25%) had locally advanced disease at the time of treatment with FOLFIRI. The median age was 60 (range, 22-86) years. The number of patients with extrahepatic cholangiocarcinoma, gall bladder cancer and intrahepatic cholangiocarcinoma were 10, 17 and 71, respectively. FOLFIRI was used as 1st, 2nd, 3rd or 4th – Nth lines in eight, 50, 36 and four patients, respectively. Median duration on FOLFIRI in the entire cohort was 2.2 (range, 0.5-8.4) mo. The median PFS and overall survival were 2.4 (95%confidence interval (CI): 1.7-3.1) and 6.6 (95%CI: 4.7-8.4) mo, respectively. Median PFS for patients treated with FOLFIRI in 1st, 2nd, 3rd or 4th – Nth lines were 3.1, 2.5, 2.3 and 1.5 mo, respectively. Eighteen patients received concurrent bevacizumab (*n* = 13) or EGFR-targeted therapy (*n* = 5) with FOLFIRI, with a median PFS of 2.7 mo (95%CI: 1.7-5.1).

***CONCLUSION***

In this largest multi-institution retrospective review of 98 patients with BTC treated with FOLFIRI, efficacy appears to be modest with outcomes similar to other cytotoxic chemotherapy regimens.

**Key words:** Biliary tract neoplasms; Fluorouracil; Irinotecan; Cholangiocarcinoma; Retrospective studies

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** We retrospectively analyzed patients with advanced biliary tract cancers treated with 5-fluorouracil plus irinotecan at three institutions, MD Anderson, University of Michigan and Mayo Clinic in Jacksonville. We identified 98 patients with a median age of 60 years, most of whom (72%) had intrahepatic cholangiocarcinoma. Fifty and 36 patients were treated in the second and third-line settings, respectively. The median progression-free survival and overall survival were 2.4 (95% confidence interval: 1.7-3.1) and 6.6 (95% confidence interval: 4.7-8.4) mo, respectively.

Mizrahi JD, Gunchick V, Mody K, Xiao L, Surapaneni P, Shroff RT, Sahai V. multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers. *World J Gastrointest Oncol*

2020; 12(1): 83-91

URL: https://www.wjgnet.com/1948-5204/full/v12/i1/83.htm

DOI: https://dx.doi.org/10.4251/wjgo.v12.i1.83

**INTRODUCTION**

Biliary tract cancers (BTCs) are rare but aggressive malignancies that arise from epithelial cells in the bile ducts or gallbladder. BTCs are anatomically classified as intrahepatic and extrahepatic (perihilar and distal) cholangiocarcinoma (CCA) and gallbladder carcinoma (GBCA)[1-3].

In the United States alone, more than 12000 people are estimated to be diagnosed with BTC in 2019[4]. Advanced BTCs are considered aggressive cancers with a reported median overall survival (OS) of approximately 12 mo*.* Over 85000 people lost their lives to BTC between 1999 and 2014[5], and mortality rates continue to rise[5,6]. It is clear that more effective management strategies are needed to reverse these rising rates, particularly for patients with locally advanced unresectable or metastatic BTCs. Standard of care first-line therapy for these patients involves multi-agent chemotherapy with gemcitabine and cisplatin[7-9]. In the phase 3 ABC-02 trial published in 2010, this gemcitabine and cisplatin was demonstrated to improve median OS to 11.7 mo compared to 8.1 mo with gemcitabine alone. However, durable response rates are infrequent, and a substantial number of patients progress quickly. Additional strategies and subsequent lines of therapy remain largely investigational with no clear standard at present, although FOLinic acid and Fluorouracil in combination with either OXaliplatin (FOLFOX) or IRInotecan (FOLFIRI) are often used[10,11].

The efficacy of FOLFIRI as a first or second-line treatment has been previously assessed in small retrospective studies. In a single institution review of 17 patients with advanced BTC treated with FOLFIRI as first-line therapy, the authors noted a median progression free survival (PFS) and OS of 2.6 and 6.5 mo, respectively[12]. In another retrospective analysis of 64 patients with advanced BTC treated with either FOLFIRI or XELIRI as second-line therapy, Brieau *et al*[10] observed a similar median PFS and OS of 2.6 and 6.2 mo, respectively. Additionally, a smaller retrospective analysis of five BTC patients treated with either FOLFIRI or FOLFOX as second-line therapy reported a median PFS and OS of 4.4 and 6.1 mo, respectively[13].

The primary objective of this retrospective analysis was to identify the efficacy of irinotecan-based regimens in the management of patients with advanced BTC in a larger multi-institutional cohort.

**MATERIALS AND METHODS**

***Study cohort***

The study was individually approved by the institutional review boards at University of Michigan, University of Texas MD Anderson Cancer Center and Mayo Clinic Cancer Center at Jacksonville. The informed consent was waived for this HIPAA compliant retrospective study. The eligibility criteria included patients aged 18 years or older with pathologic confirmation of BTC and advanced unresectable or metastatic disease on imaging. Eligible subjects must have received irinotecan-based systemic chemotherapy. Patients with ICD9 and ICD10 diagnosis codes for BTC were retrospectively identified at each institution with at least one encounter between January 2007 and October 2017. Data were collected on patient demographics, subtype of BTC, response per RECIST v1.1, progression and survival. In addition, genomic analysis data were also collected, when available.

***Statistical analysis***

Descriptive statistics such as mean, standard deviation, median and range, frequency and percentage were used to summarize patient characteristics. The Kaplan-Meier method was applied to estimate survival outcomes (Figure 1), *i.e.*, OS and PFS, and the log rank test was used for comparison of these outcomes between subgroups of patients. The OS time was calculated as the time period from the date of the treatment start to the date of death or to the date of the last follow-up for patients alive, and patients alive were censored for the analysis of OS. The PFS time was calculated as the time period from the date of start of treatment to the date of progression or death, whichever occurred first; and patients alive and without progression were censored to the date of the last follow-up. SAS software v9.4 (SAS institute Inc., Cary, NC, United States) and Splus software v8.2 (TIBCO Software Inc., Palo Alto, CA, Unites States).

**RESULTS**

A total of 98 consecutive patients who met the eligibility criteria were included in the analysis. The median age was 60 years (range, 22-86 years), and 46 (46.9%) subjects were women. Sixty-one patients were identified at MD Anderson, 26 at University of Michigan, and 11 at Mayo Clinic Cancer Center in Jacksonville. Seventy-four (75%) patients had distant metastases at the time of treatment with FOLFIRI, while 24 (25%) had locally advanced disease. The majority of patients had intrahepatic CCA (*n* = 71), compared with 17 with GBCA and 10 with extrahepatic CCA. The patient baseline characteristics are detailed in Table 1.

The median duration on FOLFIRI, or FOLFIRI-containing regimens, was 2.2 mo (range, 0.5 to 8.4), and the median PFS was 2.4 mo (95% confidence interval (CI): 1.7-3.1) for the entire cohort. The median PFS for patients treated with FOLFIRI as 1st, 2nd, 3rd or 4th – Nth line therapy was 3.1 (95%CI: 1.4-4.8), 2.4 (95%CI: 1.8-3.7), 2.3 (95%CI: 1.5-3.1) and 1.5 (95%CI: 0.9-2.0) mo, respectively. The median OS for patients treated with FOLFIRI as 1st, 2nd, 3rd or 4th – Nth line therapy was 12.3 (95%CI: 5.6-23.4), 7.7 (95%CI: 4.9-10.5), 5.0 (95%CI: 3.6-7.3) and 7.5 (95%CI: 5.2-9.8) mo, respectively. The median OS for the cohort was 6.6 mo (95%CI: 4.7-8.4) from start of therapy. The best overall response rate was 9.8% with a disease control rate of 45.1%.

Thirteen patients received vascular endothelial growth factor targeted therapy with bevacizumab, and five patients received anti-epidermal growth factor receptor therapy with erlotinib (*n =* 4) and panitumumab (*n =* 1) concurrently with FOLFIRI. Patients in both of these groups of patients exhibited a median PFS of 2.7 mo.

There was no statistically significant difference in median PFS in patients with locally advanced disease compared with those with distant metastases (3.2 *vs* 2.1 mo, *P =* 0.16) at the time of FOLFIRI treatment. There was a trend towards prolonged median OS in patients with locally advanced cancer compared with those with distant metastases (9.3 *vs* 5.6 mo, *P =* 0.08) (Table 2).

Thirty-four (35%) of the patients included in the study had genomic profiling of their BTC completed, including five with extrahepatic CCA, 27 with intrahepatic CCA and two with GBCA. The genomic profiling results are summarized in Table 3. The most frequent alterations identified included mutations in *TP53* (35.3%), *IDH1* and *IDH2* (29.4%) and *KRAS* (20.6%) genes. *FGFR*2 fusions were identified in four patients with intrahepatic CCA and two patients with extrahepatic CCA, however, the *IDH1* and *IDH2* mutations were restricted to the intrahepatic subtype.

**DISCUSSION**

In this multi-institution retrospective study, FOLFIRI, or FOLFIRI-containing regimens had modest efficacy with a median PFS of 2.4 mo and OS of 6.6 mo in patients with advanced unresectable or metastatic BTC. To our knowledge, this is the largest analysis of outcomes with FOLFIRI in BTCs. Expectedly, patients treated with FOLFIRI earlier in the course of their therapy tended to have longer PFS(*P =* 0.53), likely due to use of other 5-fluorouracil (5-FU) containing regimens prior to FOLFIRI and development of multi-drug resistance. Additionally, patients with locally advanced stage may have longer PFS (3.2 *vs* 2.1 mo; *P =* 0.16) compared to those with distant metastasis.

The majority of the patients included in our analysis had intrahepatic CCA (72%). This subtype of BTC may be associated with better outcomes compared to extrahepatic CCA and GBCA[14], which could potentially bias our results. However, a difference in survival was not seen in our patients based on subtype of BTC, though the sample size of patients with extrahepatic CCA and GBCA was small.

The survival outcomes we describe are comparable to those reported by Brieau *et al*[10] and Moretto *et al*[12] utilizing FOLFIRI and similar to published data regarding other chemotherapy regimens, such as FOLFOX in this patient population[15,16]. FOLFOX has been evaluated in multiple prospective studies as second-line therapy with a reported time to progression of 3.1 mo in a 37 patient phase II trial from China[17] and a PFS of 3.9 mo in a 66 patient observational study from Japan[18]. A retrospective analysis of 144 patients with BTCs treated with second-line chemotherapy (70% regimens 5-FU based) at a single institution in Germany found an overall response rate of 9.7% with a disease control rate of 33.6% and median OS of 9.9 mo[19]. An additional retrospective study of 18 patients from an institution in Chile showed a median PFS and OS of 3.2 and 4.6 mo, respectively[16]. The results of the phase III ABC-06 trial in which patients with locally advanced or metastatic BTCs were randomized to FOLFOX *versus* best supportive care are currently awaited[20]. There are several other clinical trials accruing patients for second-line therapy, including the phase Ib/II trial evaluating the combination of 5-FU, folinic acid and nanoliposomal irinotecan in conjunction with an anti-PD1 antibody nivolumab (BilT-03)[21].

In the subgroup of 18 patients who were treated concurrently with either anti-EGFR or anti-vascular endothelial growth factor targeted therapy, there did not appear to be a clinical benefit of the additional drug, though this was a small cohort. This is in contrast to a single institution analysis from France of 13 patients with metastatic intrahepatic CCA treated with FOLFIRI with bevacizumab as second-line therapy that reported a best overall response rate of 38.4%, median PFS of 8 mo and OS of 20 mo[22].

We identified no significant correlation between specific somatic mutations and patient outcomes or response to FOLFIRI, though this conclusion is limited by the small number of patients in our study. Recently, the most promising therapeutic advances in BTC have resulted from the identification and targeting of actionable driver somatic mutations. Multiple phase II clinical trials have yielded encouraging results by taking advantage of driver mutations such as *FGFR*, *IDH1*, *IDH2* and *BRAF*[23-26]. However, most patients with BTCs do not harbor mutations that are currently targetable, limiting the benefits of these recent advances to only a select cohort.

Given the lack of other standard therapies for patients with BTCs who have progressed on first-line therapy, our results indicate that FOLFIRI may indeed have a role in these patients. The results of our study further emphasize the need for more effective treatment options for patients with advanced unresectable or metastatic BTCs after failure of first-line systemic chemotherapy, especially in absence of actionable driver mutations.

**ARTICLE HIGHLIGHTS**

***Research background***

Biliary tract cancers (BTC) are aggressive malignancies without an established standard of care for advanced disease after progression on first-line combination chemotherapy with gemcitabine plus cisplatin. Fluoropyrimidine-based therapies, such as 5-fluorouracil plus either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are commonly used in this setting. There is limited data on the efficacy of such regimens in patients with BTCs, particularly in the patients who have progressed on first-line therapy.

***Research motivation***

There exists a need for evidence-based treatment of patients with advanced BTCs in the pre-treated setting. Only small, primarily single-institution analyses have been published about the role of FOLFIRI in this population. We sought to combine the experiences of multiple institutions to provide the largest dataset with this regimen.

***Research objectives***

Our study assessed the efficacy of FOLFIRI in patients with BTC by measuring progression-free survival and overall survival.

***Research methods***

We retrospectively identified patients with advanced, unresectable BTC who were treated with FOLFIRI at three institutions: MD Anderson, University of Michigan and Mayo Clinic in Jacksonville. We collected data on survival, response per RECIST v1.1, patient demographics and tumor characteristics.

***Research results***

Ninety-eight patients were included in our analysis, most of whom were treated in the second and third-line setting. Median duration on FOLFIRI was 2.2 mo. Median progression-free survival was 2.4 mo (95%CI: 1.7-3.1), and median overall survival was 6.6 mo (95%CI: 4.7-8.4).

***Research conclusions***

The efficacy of FOLFIRI for patients with BTCs appears to be modest with survival outcomes that are similar to historical controls of other retrospectively examined second-line cytotoxic therapy options.

***Research perspectives***

Based on this multi-institutional analysis, FOLFIRI seems to have a limited role in the treatment of patients with BTCs, though there are no prospective studies that have assessed this regimen in this patient population. The recently reported results of the randomized phase III ABC-06 trial demonstrating an increase in OS with modified FOLFOX plus active symptom control compared to active symptom control alone likely makes this a more appealing treatment option for most patients who have progressed on gemcitabine plus cisplatin.

**REFERENCES**

1 **Bridgewater J**, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, Pawlik TM, Gores GJ. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. *J Hepatol* 2014; **60**: 1268-1289 [PMID: 24681130 DOI: 10.1016/j.jhep.2014.01.021]

2 **Bridgewater JA**, Goodman KA, Kalyan A, Mulcahy MF. Biliary Tract Cancer: Epidemiology, Radiotherapy, and Molecular Profiling. *Am Soc Clin Oncol Educ Book* 2016; **35**: e194-e203 [PMID: 27249723 DOI: 10.14694/EDBK\_160831]

3 **Wistuba II**, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. *Nat Rev Cancer* 2004; **4**: 695-706 [PMID: 15343276 DOI: 10.1038/nrc1429]

4 **Siegel RL**, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin* 2019; **69**: 7-34 [PMID: 30620402 DOI: 10.3322/caac.21551]

5 **Yao KJ**, Jabbour S, Parekh N, Lin Y, Moss RA. Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National Center for Health Statistics Database. *BMC Gastroenterol* 2016; **16**: 117 [PMID: 27655244 DOI: 10.1186/s12876-016-0527-z]

6 **Khan SA**, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. *HPB (Oxford)* 2008; **10**: 77-82 [PMID: 18773060 DOI: 10.1080/13651820801992641]

7 **Valle J**, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators. Cisplatin plus gemcitabine *vs* gemcitabine for biliary tract cancer. *N Engl J Med* 2010; **362**: 1273-1281 [PMID: 20375404 DOI: 10.1056/NEJMoa0908721]

8 **Okusaka T**, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, Nagino M, Kondo S, Nagaoka S, Funai J, Koshiji M, Nambu Y, Furuse J, Miyazaki M, Nimura Y. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. *Br J Cancer* 2010; **103**: 469-474 [PMID: 20628385 DOI: 10.1038/sj.bjc.6605779]

9 **Park JO**, Oh DY, Hsu C, Chen JS, Chen LT, Orlando M, Kim JS, Lim HY. Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. *Cancer Res Treat* 2015; **47**: 343-361 [PMID: 25989801 DOI: 10.4143/crt.2014.308]

10 **Brieau B**, Dahan L, De Rycke Y, Boussaha T, Vasseur P, Tougeron D, Lecomte T, Coriat R, Bachet JB, Claudez P, Zaanan A, Soibinet P, Desrame J, Thirot-Bidault A, Trouilloud I, Mary F, Marthey L, Taieb J, Cacheux W, Lièvre A. Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues. *Cancer* 2015; **121**: 3290-3297 [PMID: 26052689 DOI: 10.1002/cncr.29471]

11 **Chun YS**, Javle M. Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma. *Cancer Control* 2017; **24**: 1073274817729241 [PMID: 28975832 DOI: 10.1177/1073274817729241]

12 **Moretto R**, Raimondo L, De Stefano A, Cella CA, Matano E, De Placido S, Carlomagno C. FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience. *Anticancer Drugs* 2013; **24**: 980-985 [PMID: 23928570 DOI: 10.1097/CAD.0b013e328364e66b]

13 **Fiteni F**, Jary M, Monnien F, Nguyen T, Beohou E, Demarchi M, Dobi E, Fein F, Cleau D, Fratté S, Nerich V, Bonnetain F, Pivot X, Borg C, Kim S. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy. *BMC Gastroenterol* 2014; **14**: 143 [PMID: 25117717 DOI: 10.1186/1471-230X-14-143]

14 **Lamarca A,** Ross P, Wasan HS, Hubner RA, McNamara MG, Lopes A, Manoharan P, Palmer D, Bridgewater J, Valle JW. Advanced intrahepatic cholangiocarcinoma: post-hoc analysis of the ABC-01, -02 and -03 clinical trials. *J Natl Cancer Inst* 2019 [PMID: 31077311 DOI: 10.1093/jnci/djz071]

15 **Rogers JE**, Law L, Nguyen VD, Qiao W, Javle MM, Kaseb A, Shroff RT. Second-line systemic treatment for advanced cholangiocarcinoma. *J Gastrointest Oncol* 2014; **5**: 408-413 [PMID: 25436118 DOI: 10.3978/j.issn.2078-6891.2014.072]

16 **Leal JL,** Roa JC, Jarufe N, Madrid J, Ibanez C, Herrera ME, Garrido M, Nervi B. Second-line FOLFOX chemotherapy in patients with metastatic gallbladder cancer and cholangiocarcinoma. *J Clin Oncol* 2014; **32**: 322-322 [DOI: 10.1200/jco.2014.32.3\_suppl.322]

17 **He S**, Shen J, Sun X, Liu L, Dong J. A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin. *J Chemother* 2014; **26**: 243-247 [PMID: 24070164 DOI: 10.1179/1973947813Y.0000000133]

18 **Dodagoudar C**, Doval DC, Mahanta A, Goel V, Upadhyay A, Goyal P, Talwar V, Singh S, John MC, Tiwari S, Patnaik N. FOLFOX-4 as second-line therapy after failure of gemcitabine and platinum combination in advanced gall bladder cancer patients. *Jpn J Clin Oncol* 2016; **46**: 57-62 [PMID: 26603355 DOI: 10.1093/jjco/hyv148]

19 **Schweitzer N**, Kirstein MM, Kratzel AM, Mederacke YS, Fischer M, Manns MP, Vogel A. Second-line chemotherapy in biliary tract cancer: Outcome and prognostic factors. *Liver Int* 2019; **39**: 914-923 [PMID: 30716200 DOI: 10.1111/liv.14063]

20 **Valle J**. Active symptom control alone or with mFOLFOX chemotherapy for locally advanced/metastatic biliary tract cancers. [accessed 2019 Apr 25]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT01926236 ClinicalTrials.gov Identifier: NCT01926236

21 **University of Michigan Rogel Cancer Center**. Phase Ib/II trial of Nal-irinotecan and nivolumab as second-line treatment in patients with advanced biliary tract cancer. [accessed 2019 Apr 25]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://ClinicalTrials.gov/show/NCT03785873 ClinicalTrials.gov Identifier: NCT03785873

22 **Guion-Dusserre JF**, Lorgis V, Vincent J, Bengrine L, Ghiringhelli F. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. *World J Gastroenterol* 2015; **21**: 2096-2101 [PMID: 25717243 DOI: 10.3748/wjg.v21.i7.2096]

23 **Lowery MA,** Abou-Alfa GK, Burris HA, Janku F, Shroff RT, Cleary JM, Azad NS, Goyal L, Maher EA, Gore L, Hollebecque A, Beeram M, Trent JC, Jiang L, Ishii Y, Auer J, Gliser C, Agresta SV, Pandya SS, Zhu AX. Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts. *J Clin Oncol* 2017; **35**: 4015-4015 [DOI: 10.1200/JCO.2017.35.15\_suppl.4015]

24 **Javle M**, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. *J Clin Oncol* 2018; **36**: 276-282 [PMID: 29182496 DOI: 10.1200/jco.2017.75.5009]

25 **Hollebecque A,** Lihou C, Zhen H, Abou-Alfa GK, Borad M, Sahai V, Catenacci DVT, Murphy A, Vaccaro G, Paulson A, Oh D-Y, Féliz L. Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations. *Ann Oncol* 2018; **29** [DOI: 10.1093/annonc/mdy282.139]

26 **Wainberg ZA,** Lassen UN, Elez E, Italiano A, Curigliano G, Braud FGD, Prager G, Greil R, Stein A, Fasolo A, Schellens JHM, Wen PY, Boran AD, Burgess P, Gasal E, Ilankumaran P, Subbiah V. Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated biliary tract cancer (BTC): A cohort of the ROAR basket trial. *J Clin Oncol* 2019; **37**: 187-187 [DOI: 10.1200/JCO.2019.37.4\_suppl.187]

**P-Reviewer:** Cao ZF, Frena A **S-Editor:** Ma YJ

**L-Editor:** Filipodia **E-Editor:** Liu MY

**Specialty type:** Oncology

**Country of origin:** United States

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Patient baseline characteristics**

|  |  |
| --- | --- |
| Characteristic | Value |
| Total, *n* | 98 |
| Age in yr, median (range) | 60 (22-86)  |
| Gender, *n (%)* Female Male | 46 (47)52 (53) |
| Institution, *n (%)* MD Anderson Cancer Center University of Michigan Mayo Clinic Cancer Center | 61 (62)26 (27)11 (11) |
| Stage at Treatment with FOLFIRI, *n (%)* Locally advanced  Metastatic  | 24 (25)74 (75) |
| Subtype of BTC, *n (%)* Extrahepatic cholangiocarcinoma Intrahepatic cholangiocarcinoma Gallbladder carcinoma | 10 (10)71 (72)17 (17) |
| Line of Therapy, *n (%)* First Second Third Fourth or greater | 8 (8)50 (51)36 (37)4 (4) |
| Irinotecan-based regimen, *n (%)* FOLFIRI FOLFIRI + bevacizumab  FOLRIRI + anti-EGFR FOLFIRINOX FOLFIRI + nab-paclitaxel | 77 (79)13 (13)5 (5)2 (2)1 (1) |
| ECOG performance status, *n (%)* 0 1 2 3 Not documented | 11 (11)48 (49)3 (3)2 (2)34 (35) |

BTC: Biliary tract cancer; ECOG: Eastern Cooperative Group; EGFR: Epidermal growth factor receptor; FOLFIRI: Folinic acid, 5-fluorouracil and irinotecan; FOLFIRINOX: Folinic acid, 5-fluorouracil, irinotecan and oxaliplatin.

**Table 2 Subgroup analysis of median progression-free survival**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Variable | Median PFS (95%CI) | *P*-value | Median OS (95%CI) | *P* value |
| Gender Female Male |  2.4 (1.6–3.6)2.3 (1.5–3.4) | 0.65 | 6.6 (4.5–9.9)6.9 (4.6–10.3) | 0.65 |
| Subtype of BTC Extrahepatic cholangiocarcinoma Intrahepatic cholangiocarcinoma Gallbladder carcinoma |   3.7 (1.5–18.9)2.3 (1.9-2.8)2.1 (1.8–3.7) | 0.14 | 8.0 (1.8–22.3)6.5 (4.5–9.7)6.5 (5.2–10.1) | 0.61 |
| Stage at treatment with FOLFIRI Locally Advanced Metastatic |  3.2 (2.0–5.2)2.1 (1.3–3.3) | 0.16 | 9.3 (5.9–14.7)5.6 (3.5–8.8) | 0.08 |
| Line of therapy First Second Third Fourth or greater | 3.1 (1.4–4.8)2.4 (1.8–3.7)2.3 (1.5–3.1)1.5 (0.9–2.0) | 0.24 | 12.3 (5.6–23.4)7.7 (4.9–10.5)5.0 (3.6–7.3)7.5 (5.2–9.8) | 0.08 |
| ECOG performance status 0 or 1 2 or greater Undocumented | 2.5 (2.0–3.1)1.5 (0.8–4.9)2.1 (1.6–3.4) | 0.44 | 7.7 (5.6–11.9)2.9 (1.7–8.6)5.3 (3.8–8.2) | 0.03 |
| Genomic analysis *KRAS*  Wildtype Mutant *FGFR*  Wildtype Fusion *IDH1* Wildtype Mutant | 2.4 (1.1–5.1)3.7 (1.7–8.0)2.5 (1.0–6.0)4.3 (1.8–10.5)2.7 (1.2–6.0)2.1 (0.9–4.6) | 0.120.290.02  | 11.8 (5.5–25.4)7.5 (3.5–16.1)8.0 (3.3–19.4)13.4 (5.5–32.2)10.8 (4.9–23.9)4.1 (2.3–11.1) | 0.060.560.14 |

BTC: Biliary tract cancer; ECOG: Eastern Cooperative Group; FOLFIRI: Folinic acid, 5-fluorouracil, irinotecan; OS: Overall survival; PFS: progression-free survival.

**Table 3 Genomic profiling by tumor type**

|  |  |  |
| --- | --- | --- |
| Total patients profiled,*n =* 34 | Cholangiocarcinoma | Gallbladder carcinoma,*n =* 2 (6%) |
| **Extrahepatic,*****n =* 5 (15%)** | **Intrahepatic,*****n =* 27 (79%)** |
| Mutation | ***n* (% of profiled)** | ***n* (% of profiled)** | ***n* (% of profiled)** |
| *TP53* | - | 10 (37) | 2 (100) |
| *IDH1* | - | 8 (30) | - |
| *KRAS* | 1 (20) | 6 (22) | - |
| *FGFR2* | 2 (40) | 4 (15) | - |
| *IDH2* | - | 2 (7) | - |
| *PBRM1* | - | 2 (7) | - |
| *BAP1* | - | 2 (7) | - |
| *NF1* | - | 1 (4) | 1 (50) |
| *ARID1A* | - | 1 (4) | 1 (50) |
| *CDKN2A* | - | - | 1 (50) |
| *MET* | - | 1 (4) | - |
| *CCND1* | - | 1 (4) | - |
| *PBX1* | - | 1 (4) | - |
| *MYC* | - | 1 (4) | - |
| *RB1* | - | 1 (4) | - |
| *MAP3K1* | - | 1 (4) | - |
| *S76* | - | 1 (4) | - |
| *SPTA1* | - | 1 (4) | - |
| *RET* | - | 1 (4) | - |
| *ALK* | - | 1 (4) | - |
| *ATM* | - | 1 (4) | - |
| *CCNE1* | - | 1 (4) | - |
| *GNAS* | - | 1 (4) | - |
| *SMAD4* | - | 1 (4) | - |
| *PIK3CA* | - | 1 (4) | - |
| *PIK3CB* | - | 1 (4) | - |
| *PTEN* | - | 1 (4) | - |
| *PALB2* | - | 1 (4) | - |
| *ARID2* | - | 1 (4) | - |
| *BRCA2* | - | 1 (4) | - |
| *BRAF* | - | 1 (4) | - |
| *MDM2* | 1 (20) | - | - |
| *FRS2* | 1 (20) | - | - |



t/mo

Percent alive without progression

A



t/mo

Percent alive

**Figure 1 The Kaplan-Meier method was applied to estimate survival outcomes.** A: Progression-free survival; B: Overall survival.